Peter Dale

565 total citations
24 papers, 412 citations indexed

About

Peter Dale is a scholar working on Physiology, Economics and Econometrics and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Peter Dale has authored 24 papers receiving a total of 412 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Physiology, 9 papers in Economics and Econometrics and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Peter Dale's work include Asthma and respiratory diseases (10 papers), Health Systems, Economic Evaluations, Quality of Life (8 papers) and Economic and Financial Impacts of Cancer (7 papers). Peter Dale is often cited by papers focused on Asthma and respiratory diseases (10 papers), Health Systems, Economic Evaluations, Quality of Life (8 papers) and Economic and Financial Impacts of Cancer (7 papers). Peter Dale collaborates with scholars based in United Kingdom, United States and Canada. Peter Dale's co-authors include Ruth E. Brown, Jean Bousquet, Kenneth R. Chapman, Ingela Wiklund, Henrik Svedsäter, Margaret Vernon, Jill A. Bell, Richard Walker, John Hutton and David Price and has published in prestigious journals such as Blood, Allergy and Journal of Thoracic Oncology.

In The Last Decade

Peter Dale

22 papers receiving 394 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Peter Dale United Kingdom 11 245 202 71 52 39 24 412
Deborah Buchner United States 14 285 1.2× 167 0.8× 30 0.4× 73 1.4× 92 2.4× 27 525
Iain Small United Kingdom 10 347 1.4× 410 2.0× 72 1.0× 9 0.2× 34 0.9× 23 545
Leonard Fromer United States 11 263 1.1× 187 0.9× 201 2.8× 15 0.3× 24 0.6× 26 447
T. Svahn United States 6 304 1.2× 255 1.3× 24 0.3× 21 0.4× 77 2.0× 8 510
BL Barber United States 6 279 1.1× 268 1.3× 59 0.8× 41 0.8× 24 0.6× 15 482
Vivian Chia‐Rong Hsieh Taiwan 10 69 0.3× 45 0.2× 45 0.6× 18 0.3× 46 1.2× 36 354
Kathy Rickard United States 12 461 1.9× 432 2.1× 56 0.8× 13 0.3× 48 1.2× 24 589
Frank L. Custers Netherlands 8 194 0.8× 327 1.6× 22 0.3× 41 0.8× 63 1.6× 12 442
Shiva G. Sajjan United States 14 172 0.7× 123 0.6× 14 0.2× 91 1.8× 38 1.0× 23 469
Nicola Sinden United Kingdom 8 106 0.4× 294 1.5× 13 0.2× 18 0.3× 87 2.2× 9 569

Countries citing papers authored by Peter Dale

Since Specialization
Citations

This map shows the geographic impact of Peter Dale's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Dale with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Dale more than expected).

Fields of papers citing papers by Peter Dale

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Dale. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Dale. The network helps show where Peter Dale may publish in the future.

Co-authorship network of co-authors of Peter Dale

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Dale. A scholar is included among the top collaborators of Peter Dale based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Dale. Peter Dale is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Chaudhary, Mohammad A., Yong Yuan, N. Varol, et al.. (2022). Cost-effectiveness analysis of nivolumab plus ipilimumab versus platinum-doublet chemotherapy for first-line treatment of stage IV or recurrent non-small cell lung cancer in the United States. Journal of Medical Economics. 25(1). 703–711. 5 indexed citations
2.
3.
Chaudhary, Mohammad A., Yong Yuan, N. Varol, et al.. (2021). MO01.02 Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab in the First-Line Treatment of Metastatic Non-Small Cell Lung Cancer in the United States. Journal of Thoracic Oncology. 16(1). S15–S16. 1 indexed citations
4.
5.
6.
7.
Chapman, Sarah, et al.. (2017). Modelling the effect of beliefs about asthma medication and treatment intrusiveness on adherence and preference for once-daily vs. twice-daily medication. npj Primary Care Respiratory Medicine. 27(1). 61–61. 18 indexed citations
8.
9.
Clark, Marci, Susan Martin, Henrik Svedsäter, Peter Dale, & Loretta Jacques. (2014). Measurement properties of an asthma symptom and rescue medication use diary. Journal of Asthma. 52(1). 88–97. 8 indexed citations
10.
Svedsäter, Henrik, et al.. (2013). Qualitative assessment of attributes and ease of use of the ELLIPTA™ dry powder inhaler for delivery of maintenance therapy for asthma and COPD. BMC Pulmonary Medicine. 13(1). 72–72. 64 indexed citations
11.
Price, David, et al.. (2013). Types, frequency and impact of asthma triggers on patients’ lives: a quantitative study in five European countries. Journal of Asthma. 51(2). 127–135. 20 indexed citations
12.
13.
Vernon, Margaret, Ingela Wiklund, Jill A. Bell, Peter Dale, & Kenneth R. Chapman. (2012). What Do We Know about Asthma Triggers? A Review of the Literature. Journal of Asthma. 49(10). 991–998. 72 indexed citations
14.
Maguire, Lisa, et al.. (2011). PRS54 Testing of a Conceptual Model of Asthma in Adolescents. Value in Health. 14(7). A497–A497. 1 indexed citations
15.
Vernon, Margaret, Ingela Wiklund, Jill A. Bell, et al.. (2011). Asthma Control And Asthma Triggers: The Patient Perspective. A4764–A4764. 1 indexed citations
16.
Muszbek, N., Sonalee Shah, Stuart Carroll, et al.. (2008). Economic evaluation of sorafenib in the treatment of hepatocellular carcinoma in Canada. Current Medical Research and Opinion. 24(12). 3559–3569. 24 indexed citations
17.
Deniz, Baris, Gareth J. Morgan, Steve Schey, et al.. (2008). Economic Evaluation of Lenalidomide Combined with Dexamethasone for the Treatment of Multiple Myeloma in the UK. Blood. 112(11). 2400–2400. 4 indexed citations
18.
Brown, Ruth E., et al.. (2007). Cost‐effectiveness of omalizumab in patients with severe persistent allergic asthma. Allergy. 62(2). 149–153. 91 indexed citations
19.
Price, Thomas S., Jennifer L. Stevenson, Peter Dale, et al.. (2000). Genetic overlap between hyperactive symptoms and early language delay.. American Journal of Medical Genetics Part A. 96(4). 556–556. 4 indexed citations
20.
McKendry, R J, G. A. H. Wells, Peter Dale, et al.. (1996). Factors influencing the emigration of physicians from Canada to the United States.. PubMed. 154(2). 171–81. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Deborah Buchner Breakdown of academic impact, for papers by Iain Small Breakdown of academic impact, for papers by Leonard Fromer Breakdown of academic impact, for papers by T. Svahn Breakdown of academic impact, for papers by BL Barber Breakdown of academic impact, for papers by Vivian Chia‐Rong Hsieh Breakdown of academic impact, for papers by Kathy Rickard Breakdown of academic impact, for papers by Frank L. Custers Breakdown of academic impact, for papers by Shiva G. Sajjan Breakdown of academic impact, for papers by Nicola Sinden
Rankless by CCL
2026